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Ovarian Cancer G Protein-Coupled Receptor 1, a
New Metastasis Suppressor Gene in Prostate Cancer
Lisam Shanjukumar Singh, Michael Berk, Rhonda Oates, Zhenwen Zhao, Haiyan Tan, Ying Jiang,
Aimin Zhou, Kashif Kirmani, Rosemary Steinmetz, Daniel Lindner, Yan Xu

Background

Metastasis is a process by which tumors spread from primary organs to other sites in the body and is the
major cause of death for cancer patients. The ovarian cancer G protein-coupled receptor 1 (OGR1) gene has
been shown to be expressed at lower levels in metastatic compared with primary prostate cancer tissues.

Methods

We used an orthotopic mouse metastasis model, in which we injected PC3 metastatic human prostate
cancer cells stably transfected with empty vector (vector-PC3) or OGR1-expressing vector (OGR1-PC3) into
the prostate lobes of athymic or NOD/SCID mice (n = 3-8 mice per group). Migration of PC3 cells tran
siently transfected with vector control or with OGR1- or GPR4 (a G protein-coupled receptor with the
highest homology to OGR1 (-expressing vectors was measured in vitro by Boyden chamber assays. G pro
tein alpha-inhibitory subunit 1 (Gαi1) expression after treatment with pertussis toxin (PTX) was measured
using immunoblotting analysis. The inhibitory factor present in the conditioned medium was extracted
using organic solvents and analyzed by mass spectrometry.

Results

in vivo, all 26 mice carrying tumors that were derived from vector-PC3 cells developed prostate cancer
metastases (mean = 100%, 95% confidence interval [Cl] = 83.97% to 100%) but few (4 of 32) mice carrying
tumors derived from OGR1-expressing PC3 cells (mean = 12.50%, 95% Cl = 4.08% to 29.93%) developed
metastases. However, exogenous OGR1 overexpression had no effect on primary prostate tumor growth
in vivo. In vitro, expression of OGR1, but not GPR4, inhibited ceil migration (mean percentage of cells
migrated, 30.2% versus 100%, difference = 69.8%, 95% Cl = 63.0% to 75.9%; P<.001) via increased expres
sion of Gαi1 and the secretion of a chloroform∕methanol-extractable heat-insensitive factor into the condi
tioned medium through a PTX-sensitive pathway.

Conclusion

OGR1 is a novel metastasis suppressor gene for prostate cancer. OGR1's constitutive activity via Gαi
contributes to its inhibitory effect on cell migration in vitro.

J Natl Cancer Inst 2007;99:1313-27

Approximately 1.4 million new cancers were diagnosed, and more
than 564000 deaths from cancer were expected, in the United States
in 2006 (1). The majority of these cancer-related deaths will be due
to tumor metastasis rather than to the primary tumors. Thus, the
major clinical challenge is to combat systemic metastatic disease.
Unlike tumor suppressor genes, such as p53 and Rb, metastasis
suppressor genes reduce the metastatic propensity of cancer cell
lines without substantially affecting their tumorigenesis in vivo
(2-4). Well-defined metastasis suppressor genes include NM23,
MKK4, KAI1, BRMS1, KiSSl, RHOGDI2, CRSP3, and VDUP1
(2,5,6). Metastasis suppressor genes operate at different levels in
the metastatic process (2,3) through mechanisms that involve
mitogen-activated protein (MAP) kinase (ERK, p38, and JNK
kinases) regulation, integrin interaction, epidermal growth factor
desensitization, Gap junction communication, modulation of G
protein-coupled receptors or G proteins; they can also function as
coactivators of transcription and inhibitors of thioredoxin (2,3,5).
Targeting metastasis suppressor genes has high therapeutic poten
tial. Although there are many steps in metastasis, blocking only

one of these steps may potentially inhibit or prevent metastasis.
Moreover, unlike classical tumor suppressor genes, most metasta
sis suppressor genes are not mutated in tumor tissues but instead
their expression is suppressed by promoter methylation and/or
other mechanisms. Thus, restoring metastasis suppressor gene ex
pression may be sufficient to suppress tumor metastasis (5,7).

CONTEXT AND CAVEATS
Prior knowledge
Tumor metastasis is a major cause of death among cancer patients.
The expression of ovarian cancer G protein-coupled receptor 1
(OGR1) is higher in primary prostate tumors than metastases.

Study design
Mouse models of prostate cancer metastasis and in vitro migration
assays using control human prostate cancer cells and those engi
neered to overexpress OGR1.
Contributions
Cells overexpressing OGR1 formed fewer metastases in the mouse
models and migrated more slowly in vitro than control cells.

Implications
OGR1 acts as a metastasis suppressor gene in prostate cancer.

Study limitations
Only one prostate cancer cell line was used in the mouse models.
In these models, this cell line did not metastasize to bone, which is
one of the most common sites of metastasis in prostate cancer as
well as other types of cancer. Thus, how OGR1 might affect metas
tasis to bone is unknown, as is the application of these findings to
human prostate cancer.

Identifying prostate cancer-related metastasis suppressor genes
and their mechanisms of action is important for the development
of novel strategies for the prevention and treatment of metastatic
prostate tumors. An estimated 234460 new cases and 27 350 deaths
from prostate cancer were expected in the United States in 2006
(1). With the introduction of the prostate-specific antigen (PSA)
screening test, approximately 75% of prostate cancers are detected
when the disease is clinically confined to the prostate. However,
in many patients, the cancer often progresses to an androgenindependent metastatic stage for which few treatment options are
available. Several metastasis suppressor genes have been identified
in prostate cancer, including CD44, NM23, MKK4, and KAI1 (8).
G proteins and G protein-coupled receptors have important
roles in prostate cancer (9-11) and in other pathologic processes.
Of the 100 leading pharmaceutical products developed in 2000,
39 act through a G protein-coupled receptor-mediated mecha
nism, underlining the importance of G protein-coupled receptors
as important pharmaceutical targets (12). We have previously
cloned OGR1, a G protein-coupled receptor from the HEY hu
man ovarian cancer cell line (13). OGR1 and related subfamily
members GPR4, G2A, and TDAG8 mediate the functions of
several lysophospholipids, including sphingosylphosphorylcholine
(SPC), lysophosphatidylcholine (LPC), and psychosine (14-18),
which include endothelial barrier function, endothelial cell
proliferation, migration, and tube formation, T cell migration, gluco
corticoid-induced thymocyte apoptosis, and globoid cell formation.
In addition, all members of the OGR1 subfamily exhibit protonsensing properties (19,20). Using small hairpin RNA to inhibit ex
pression of GPR4 followed by replenishment with mutant GPR4, we
have shown that endogenous GPR4 mediates the proliferation,
migration, and tube formation effects of SPC. In addition, unlike ear
lier studies in HEK293 cells, for which GPR4 overexpression resulted

in increased cAMP production in response to changes in cellular pH
(19), we have shown (15) that, in endothelial cells, endogenous GPR4
does not increase cAMP production in response to pH changes.
Although more extensive work is warranted to further clarify
these apparently conflicting findings related to pH and lipid regu
lators and/or modulators, OGR1 and related G protein-coupled
receptors also possess constitutive activities that do not require
ligand binding and are not affected by pH changes (15). Many G
protein-coupled receptors undergo a spontaneous switch between
their inactive and active states (induced or stabilized by the ago
nist). When these receptors undergo agonist-independent stabili
zation of tire active state, tlrey become constitutively active, which
results in an increase in basal G protein activity. Constitutive activ
ity is observed in numerous G protein-coupled receptors (21) and
can be achieved through various mechanisms (12,21-23).
LaTulippe et al. (24) have conducted a comprehensive gene
expression analysis of prostate cancer using oligonucleotide arrays
with more than 63 000 probe sets to identify genes and expressed
sequences with substantial differential expression between non
recurrent primary prostate cancers and metastatic prostate cancers.
Interestingly, among the top 100 differentially expressed genes
that were identified in this study, OGR1 expression was shown to
be fivefold lower in tumor metastases than primary tumors (24).
In this study, we investigated the role of OGR1 in prostate can
cer metastasis using an orthotopic model in athymic (nu∕nu) and nonobese diabetic/severe combined immunodeficiency (NOD/SCID)
mice. We also investigated the effects of OGR1 expression on meta
static prostate cancer cell migration in vitro and the mechanisms
underlying these effects using stable PC3 prostate cancer cell clones.

Materials and Methods
Materials

Male athymic mice (n = 26, 5-7 weeks old; nu∕nu) were obtained
from Charles River Laboratories (Wilmington, MA). Male NOD/
SCID mice (n = 32, 5-7 weeks old) were obtained either from
Jackson Laboratory (Bar Harbor, ME) or from Dr Karen Pollok at
the Indiana University School of Medicine (Indianapolis, IN). Alice
were housed at the Cleveland Clinic’s Laboratory Animal Resource
Unit (Cleveland, OH) or at the Laboratory Animal Resource Center
at the Indiana University School ofMedicine. Immunohistochemistry
kits were obtained from Vector Laboratories (Burlingame, CA).
G protein alpha-inhibitory subunit (Gαi1) dominant-negative
cDNAs were purchased from the University of Missouri’s UMR
cDNA Resource Center (Rolla, MO). Rabbit polyclonal anti-Gαi1
antibody was from Santa Cruz Biotechnology (Santa Cruz, CA).
Mouse monoclonal anti-BrdU antibody and methylthiazolyldiphenyl-tetrazolium bromide (MTT) were obtained from Sigma
(St Louis, MO), rabbit polyclonal anti-OGR1 antibody was pur
chased from LifeSpan BioSciences (Seattle, WA), and rat monoclo
nal anti-mouse CD49b∕Pan-NK-cells antibody was purchased from
BD Biosciences (San Jose, CA).
Cell Culture

The androgen-independent metastatic human prostate cancer cell
line PC3 and the human embryonic kidney 293T (HEK293T) cell

line were purchased from American Type Culture Collection
(Manassas, VA). The immortalized human microvascular endothelial
cell line-1 (HMEC-1) was from the Centers for Disease Control and
Prevention (Atlanta, GA). PC3 and HMEC-1 cells were cultured in
RPMI-1640. C4-2 and DU145 human prostate cancer cell lines
(obtained from Dr Warren Heston at the Cleveland Clinic), and
HEK293T cells were cultured in Dulbecco’s modified Eagle medium.
Media were supplemented with 10% fetal bovine serum (FBS), 100
units/mL penicillin-streptomycin, and 2 mM glutamine. Cells were
maintained in a humidified 5% CO2 atmosphere at 37 oC.
Plasmid Construction

The pcDNA3-OGRl (human) and pcDNA3-GPR4 (human) plas
mids were generated in our laboratory as described previously
(12,21-23). OGRl-pMSCV murine stem cell virus retroviral vector
(MSCV; puromycin) expression plasmids with or without fusion
to enhanced green fluorescence protein (EGFP) were constructed.
To construct the pMSCV-3HA-OGRl-EGFP plasmid, the 3HAOGR1-EGFP fragment of the pEGFP-Nl-3HA-OGRl plasmid,
which we constructed previously (our unpublished results), was
removed by digestion with NotI and Xhol and was then inserted into
the pTriEx-1 vector (Novagen, San Diego, CA). Similarly, to con
struct the pMSCV-3HA-OGRl plasmid, the 3HA-OGR1 frag
ment was removed from pcDNA3-OGRl by digestion with HindII
and EcoRI and was then inserted into the pTriEx-1 vector. Both the
3HA-OGR1 and the 3HA-OGR1-EGFP DNA fragments were
then excised from the pTriEx-1 vector and inserted into pMSCV
(puromycin) by digestion with EcoRI and Xhol. The EGFP-coding
sequence fragment was amplified from the pEGFPNl plasmid (BD
Biosciences, Palo Alto, CA, GenBank accession code U55762) by
polymerase chain reaction (PCR) using primers 5'-ACAGTTTAA
ACTTCGAATTCTGCAGTCGACGG-3'(forward) and 5'-AAT
GCGGCCGCTTTACTTGTACAGCTCGTCCATGC-3'
(reverse) and then cloned into pMSCV (puromycin) by EcoRI and
Xhol digestion. The resulting plasmid pMSCV-EGFP was used as
the EGFP control vector. An OGR1 mutant, pcDNA3-OGRlH245F was constructed by site-directed mutagenesis. The histidine
residue of OGR1 at position 245 was replaced with phenylalanine
using the Quick Change Mutagenesis System (StrataGene Systems
Inc, Lajolla, CA) and tire pcDNA3-OGRl plasmid as the template.
The mutagenesis was confirmed by sequence analysis.
All plasmid constructs were transformed in DH5α (Invitrogen,
Carlsbad, CA)-competent Escherichia coli, and selected colonies
were cultured. Plasmid DNA was purified using either the
GenElute Five-Minute Plasmid Miniprep Kit (Sigma) or QIA
prep MINIprep (Qiagen, Valencia, CA). The DNA sequences and
reading frames were verified by sequence analysis at the Molecular
Biotechnology core facility at the Cleveland Clinic using an ABI
Prism 377 Automated DNA Sequencer (Applied Biosystems,
Foster City, CA).
Transient Transfection and Generation of Stable Clones

HEK293T cells were cotransfected with each of the plasmid
constructs pMSCV-3HA-OGRl, pMSCV-3HA-OGRl-EGFP,
pMCV-EGFP, or pMSCV empty vector and packaging plasmid
using a calcium phosphate transfection kit (Invitrogen) according
to the manufacturer’s instructions. The media containing the virus

were collected 3 days after transfection, and the viral particles were
collected by centrifugation at 1620gfor 30 minutes at 4 oC. PC3 cells
were plated into six-well tissue culture dishes and infected with
1-2 mL of the virus-containing media from transfected HEK293
cells. Infected cells were transferred to 10-cm dishes 3 days later.
Stable single PC3 cell colonies (monoclonal) or pooled cells
(polyclonal) were selected with puromycin (2.5 μg∕mL). Clones
expressing OGR1 or vector were designated as OGR1-PC3,
OGR1-EGFP-PC3, vector-PC3, and EGFP-PC3. For PC3 celltransient transfection, PC3 cells were transfected with 1.0-1.5 μg
of pcDNA3-OGRl, pcDNA3-GPR4, or pcDNA3-OGRl-H245F
or were cotransfected with pcDNA3-OGRl and pcDNA3-Gαil
dominant-negative plasmids in six-well plates using lipofectamine
2000 (Invitrogen) according to the manufacturer’s protocol. C4-2
and DU145 cells were transiently transfected with 1.0-1.5 μg of the
pcDNA3 empty vector or the pcDNA3-OGRl plasmid. Cellular
assays were conducted 48-72 hours after transfection.
Human Prostate Cancer Metastasis Orthotopic
Mouse Model

All mouse studies were approved by the Indiana University School
of Medicine or the Cleveland Clinic Institutional Animal Care and
Use Committees. In these studies, 5- to 7-week-old male athymic
(nu∕nu, n = 26) or NOD/SCID (n = 32) mice were anesthetized
using isoflurane (2%-4%), nembutal (50 mg∕kg), or ketamine
(200 mg∕kg). An abdominal incision (5-10 mm) was made in each
mouse, and the prostate gland was exposed and injected once with
either OGR1-PC3 (n = 7), OGR1-EGFP-PC3 (n = 25), vector-PC3
(n = 3), or EGFP-PC3 (n = 23) cells (5.0 x 106 cells in 40-50 μL
phosphate-buffered saline [PBS: sodium chloride, 145 mM {O.85%}
in phosphate buffer, 150 mM {Sigma}]). After injection, prostate
glands were placed back into the peritoneal cavity, and the incisions
were surgically closed.
Postsurgical and Necropsy Procedures

Following tumor cell injection, mice were observed daily for signs of
tumor development, including hunched posture, abdominal bloat
ing, or loss of mobility. Alice were killed on day 45 when tumors had
metastasized to other organs in the control mice by CO2 inhalation,
and necropsies were performed to assess tumor growth and metas
tasis. Metastases in different organs were measured and counted
using fluorescence or light microscopy. All primary prostate tumors
and metastases were harvested, fixed in 10% neutral buffered forma
lin, embedded in paraffin, sectioned into 5-μm slices, and then either
stained with hematoxylin and eosin or immunostained using anti
bodies as described below. Bones (ribs, tibia, and femur) from mice
injected with control EGFP-PC3 or OGR1-EGFP-PC3 clones
were removed, dissected free of most adherent tissues, and observed
immediately with epifluorescence microscopy. In addition, bones
were fixed in 4% paraformadehyde and decalcified in 14% EDTA
(pH 7.4) for 2 weeks at 4 oC. The decalcified bones were sectioned
and observed using epifluorescence microscopy.
Microscopy and Reverse Transcription-Polymerase
Chain Reaction to Detect Metastases

Tumors expressing EGFP were observed using a Leica fluorescent
stereomicroscope equipped with green (fluorescein, 480Ex∕530Em)

and red (TexasRed, 560Ex∕630Em) filters (model MZ 16FA). The
green and red images were merged, and the metastases in the
mice that had been injected with OGR1-EGFP-PC3 and EGFPPC3 were compared using Image ProPlus software (Media cyber
netics, Bethesda, MD). A light stereo microscope (model
SMZ1000, Nikon, Fryer Co Inc, Huntley, IL) equipped with a
Nikon digital camera (DXM1200F) was used to analyze tumor
size and metastases to different organs. For quantification of in
vitro fluorescence, images were captured from four fields per well
(three wells per sample) at ×40 magnification using a Nikon epifluorescence microscope. Images were saved in JPEG format and
converted into Canvas 9 (ACD System, Miami, FL) format for
analysis. Background fluorescence was approximated from a well
of control PC3 cells (i.e., that had not been transfected with an
EGFP-containing vector) and subtracted from the levels of fluo
rescence from test cells.
To detect potential microscopic tumors, small portions of liver
(three to four portions per mouse) were collected from seven to
eight mice from each group of EGFP-PC3 or OGR1-EGFP-PC3.
Total RNA was isolated, and reverse transcription (RT)-PCR was
carried out using primers specific for EGFP and β-actin. The
primers for EGFP were 5'-CCT ACG GCG TGC AGT GCT
TCA GC-3' (forward) and 5'-CGG CGA GCT GCA CGC TGC
GTC CTC-3' (reverse). The primers for β-actin were 5'-AAG
GCC AAC CGT GAA AAG ATG ACC-3' (forward) and 5'-ACC
GCT CGT TGC CAT TAG TGA TGA-3' (reverse) (GenBank
accession number NM_OO7393).
In Vivo Primary Tumor Cell Proliferation Assay

Cell proliferation in primary prostate tumors was assessed using
5-bromo-2-deoxyuridine (BrdU; Sigma) staining. Mice were in
jected intraperitoneally with 40 mg/kg body weight of BrdU. After
2 hours, mice were killed as described above, and primary prostate
tumors were excised, formalin fixed, and embedded in paraffin
(from each primary tumor of seven to eight mice per group).
Immunohistochemistry for OGR1, 5-Bromo2-Deo×yuridine, and Natural Killer Cells

Immunostaining was performed on primary tumor sections using
the Vectastain Universal ABC kit (Vector Laboratories). Briefly,
paraffin-embedded tissues were deparaffinized with xylene or
Histo-Clear (National Diagnostics, Atlanta, GA) and dehydrated
using decreasing gradient alcohol washes (100%, 95%, and 80%
ethanol). Antigen retrieval was performed by microwaving the sec
tions in 10 mM citrate buffer for 1 minute. Sections were then
blocked with horse serum (included in the Vectastain Universal
ABC kit) (2.5% in PBS) and incubated overnight with rabbit
anti-human OGR1 polyconal antibody (1:500 dilution) or for 30
minutes with rat anti-mouse monoclonal CD49b (NK1.1, 1:250
dilution) or mouse monoclonal anti-BrdU sera (1: 500). Sections
were then incubated with biotinylated pan-specific universal
secondary antibody (according to the user manual from Vector
Laboratories) for 10 minutes, followed by incubation with
streptavidin-peroxidase for 5 minutes and 3, 3'-diaminobenzidine.
The staining levels in the negative controls (duplicate slides
without primary antibodies) were used as background. All cells
that stained brown were considered positive. Immunostaining was

scored (×20 magnification) on triplicate tissue sections from
each group of mice by an independent observer blindly (Dr
Weiling Xu).
Terminal Transferase dUTP Nick End Labeling Assay to
Detect Cells Undergoing Apoptosis

Terminal transferase dUTP nick end labeling assays were per
formed to detect apoptotic cells in the primary tumors by using
an Apoptag Peroxidase In Situ Apoptosis Detection Kit
(Chemicon, Temecula, CA). Tumor sections (from seven to eight
mice per group) were deparaffinzied and rehydrated as mentioned
above and then incubated in 20 μg∕mL proteinase K for 15 min
utes at room temperature and washed twice with distilled water.
Next, the endogenous peroxidase activity in the tumor sections
was blocked by incubation for 5 minutes with 3 % H2O2 in PBS,
followed by incubation for 10 seconds with equilibration buffer.
The sections were then incubated for 1 hour at 37 oC with termi
nal deoxynucleotidyl transferase enzyme in reaction buffer
(according to the manufacturer’s instructions). The reaction was
terminated by incubation with stop buffer at room temperature.
Sections were then incubated with peroxidase-conjugated antidigoxigenin antibody for 30 minutes, and the reaction was devel
oped with diaminobenzidine substrate for 4 minutes at room
temperature.
RNA Isolation and RT-PCR to Measure OGR1 and
EGFP mRNA Expression

Total RNA was extracted from 5.0 × 105 to 6.0 x 105 OGR1-PC3,
vector-PC3, DU145, and C4-2 cells or from 2.5 mg of
primary tumors or livers from mice injected with vector-PC3 and
OGR1-PC3 clones using the total SV RNA isolation kit (Promega,
Madison, WI) following the manufacturer’s protocol. First-strand
cDNA was synthesized from 2.5 μg DNA-free total RNA using
the SuperScript II first-stand synthesis kit (Invitrogen). OGR1
expression levels were analyzed by semi-quantitative RT-PCR.
Glyceraldehyde-3-phosphate dehydrogenase served as the
loading control. RT-PCR for the OGR1-EGFP fusion protein
was performed with an OGR1-specific forward primer (5'TCCGGGAAAAGCGGGGC-3') and an EGFP-specific reverse
primer (5'-TGCAGAAATTCTTACTTGTACAGCTCGTCCA
TG-3'). For OGR1, RT-PCR was performed using OGR1-specific
forward (5'-CTGCCTGTCCCTCTACTTCG-3') and reverse
(5'-TGTTCTCGTACAGGAGGATGC-3') primers. Quantita
tive PCR was performed with primers obtained from Gorilla
Genomics, Inc (Alameda, CA). The primer sequences for
OGR1 were 5'-CACCGTGGTCATCTTCCTG-3' (forward)
and 5'-GGAGAAGTGGTAGGCGTTGA-3' (reverse). The β2microglobulin housekeeping gene (NM_004048) was used as the
loading control. The primer sequences used to amplify the β2microglobulin were 5'-ACTGGTCTTTCTATCTCTTGTACT-3'
(forward) and 5'-CTGCTTACATGTCTCGATCC-3' (reverse).
Experiments were performed three times in triplicate for each cell
line. The primers used for measuring EGFP mRNA in the liver
tissues were 5'-GACGACGGCAACTACAAGA-3' (forward) and
5'-GATGCCGTTCTTCTGCTT-3' (reverse). PCR was per
formed with RNA isolated from three to four portions of each liver
per mouse from 16 mice per group.

Immunoblot for G protein alpha-inhibitory subunit 1

Vector-PC3 and OGR1-PC3 cells (at 80%-85% confluence
in a six-well plate) were treated with or without actinomycin D
(500 ng/mL Calbiochem, San Diego, CA) for 24 hours. Total
protein was extracted and quantified using the BCA Protein Assay
Kit (Pierce, Rockford, IL). Equal amounts of protein per lane were
separated on 10% sodium dodecylsulfate minigels and then electrophoretically transferred to Immobilon P polyvinylidene difluoride
membranes (Millipore, Billerica, MA). Membranes were blocked in
5% nonfat dry milk in Tris-buffered saline containing 0.2% Tween
20 (TBST) for 2 hours at room temperature and then incubated
with rabbit polyclonal anti-Gαil antibody overnight at 4 oC (1:1000
dilution), washed three times with TBST, incubated with goat
anti-rabbit IgG horseradish peroxidase-conjugated secondary
antibody (1:4000 dilution), and finally washed three times with
TBST. Antibody-protein complexes were visualized using the
ECL Western Blotting Detection System (Amersham Biosciences,
Piscataway, NJ). The membranes were then stripped and reblotted
with monoclonal mouse β-actin antibody (1:3000 dilution) to
assess protein loading and transfer. Immunoblotting was performed
three times using vector-PC3, EGFP-PC3, OGR1-PC, and OGR1EGFP-PCs cells.
pH Effect Studies

To test the effect of pH on tire secretion of arachidonic acid (AA)
and LPC in OGR1-PC3 cells, physiologic salt solutions (PSS; 130
mM NaCl, 0.9 mM NaH2PO4, 5.4 mM KC1, 0.8 mM MgSO4, 1 mM
CaCl2, 25 mM glucose, and 20 mM HEPES) at three different
pHs (6.8, 7.4, and 7.8) were prepared (25). Vector-PC3 and OGR1PC3 cells were incubated with each of the PSS for 90 minutes in a
humidified 5% CO2 atmosphere chamber at 37 oC. Cell superna
tants were collected, and AA and LPC were extracted as described
below. Five independent experiments were performed in triplicate.
Preparation of Conditioned Media

Vector-PC3 and OGR1-PC3 cells were grown in 10-cm2 tissue
culture plates to 85%-95% confluence. The media was then
removed, the cells were washed twice with PBS, and serum-free
RPMI-1640 medium containing 100 units/mL penicillin-strepto
mycin and 2 mM glutamine (6 mL) was added to each plate. The
conditioned medium was collected after 12-16 hours of incuba
tion and stored at -80 oC in glass or siliconized plastic tubes before
analysis. For experiments using pertussis toxin (PTX) treatment,
vector-PC3 and/or OGR1-PC3 cells were plated as above and pretreated with 100 nM PTX for 16 hours. The PTX media was
removed, and the cells were washed twice with PBS and incubated
in either serum-free or complete medium (RPMI-1640 with 10%
FBS), and medium was collected as described above. This proce
dure was performed three times in triplicate.
Migration Assay

Parental PC3 cells and PC3 clones were cultured to 85%-95%
confluence and subjected to serum starvation for 16 hours before
assay. Cells were dissociated by incubation with trypsin-EDTA
(0.05% trypsin, 53 mM EDTA), washed twice with PBS, and
counted using a hemocytometer. The lower side of the insert of the
24-well transwell migration chamber membrane (8.0 μm pore size;

Corning Inc, New York, NY) was coated with 10 pL of 10 μg∕mL
vitronectin (Chemicon,) and dried at room temperature. Vitronectin
was chosen among several ECM proteins tested because it was the
substrate on which OGR1 had the maximal inhibitory effect on
cell migration; thus, differences between groups could be readily
observed. Serum-free media (300 pL) was added to each lower
chamber of the 24-well transwell. Inserts (the upper chambers) were
then placed in the wells (the lower chambers). Cells (0.5 × 105 to
1.0 × 10s in 300 pL serum-free media) were added to each upper
chamber and incubated for 4.5 hours. Nonmigrating cells were re
moved with a cotton swab. The cells that migrated to the lower
phase of the upper chamber were then fixed in methanol for 30 min
utes and stained with crystal violet (1 g∕mL, Fluka Chemical Corp,
Milwaukee, WI) for 30 minutes at room temperature. Excess stain
was removed with water, and the chambers were air-dried. Cells
were then visualized under the microscope and quantified by count
ing the number of cells in three randomly chosen fields. At least 10
independent experiments were performed, each in triplicate.
To study the effect of conditioned media on cell migration,
parental PC 3 cells were serum starved for 16 hours, treated with
trypsin-EDTA, washed twice with PBS, counted, and then prein
cubated with conditioned media (see above) or lipid extracts from
conditioned media (see below for lipid extraction) for 30 minutes
on a rotator in a cell culture incubator before being used for
migration assays. At least eight independent experiments were
performed, each in triplicate.
Transendothelial Migration Assay

A monolayer of HMEC-1 cells was generated on 24-well transwell
migration chambers by seeding 5.0 × 106 cells. Control EGFPPC3 or OGR1-EGFP-PC3 cells were added directly on top of the
endothelial cell layer, as described above. Non-GFP cells were
treated with calcein AM (10 pmol/mL) (Invitrogen) for 30 min
utes, washed twice, and then added on top of the endothelial cell
layer. Migrated cells were fixed with methanol for 20 minutes and
counted using a fluorescence microscope. Three independent
experiments were performed, each in triplicate.
In Vitro Cell Proliferation Assay

OGR1-PC3, OGR1-EGFP-PC3, vector-PC3, and EGFP-PC3
clones were seeded in 48-well plates (5000 cells per well). After 6
hours, the medium was replaced with RPMI-1640 supplemented with
or without 2% FBS. Cells were stained with 2% trypan blue and cell
proliferation at 24, 48, and 72 hours was assessed by counting using a
hemocytometer or by MTT assay. For the MTT assay, 30 pL of
MTT (5 mg/mL in PBS) was added to each well containing 200 pL
media and incubated at 37 oC for 3 hours. After the cell culture
medium was removed, 200 pL of dimethyl sulfoxide was added to each
well to solubilize the dye. Absorbance was examined at 570 nm using
a Victor3 plate reader (PerkinElmer Life and Analytical Sciences,
Shelton, CT). Three independent experiments were performed
(using EGFP-PC3 and OGR1-EGFP-PC3 cell hnes) in triplicate.
Heat Treatment, Lipid Extraction From Conditioned
Media, and Mass Spectrometry Analyses

To study the effect of heat-treated conditioned media on paren
tal PC3 cell migration, conditioned media from OGR1-PC3,

OGR1-EGFP-PC3, vector-PC3, or EGFP-PC3 cells were
heated in an immersion circulating water bath (PolyScience,
Niles, IL) at 95 oC for 30 minutes. The media were centrifuged
at 13 400g for 10 minutes at 4 oC and used for migration assays. At
least five independent experiments were performed for each cell
line, each in triplicate.
LPC was extracted from the conditioned media from vectorPC3 or EGFP-PC3 and OGR1-PC3 or OGR1-EGFP-PC3 using
the method of Bligh and Dyer (26). In brief, 10 μL of 12:0 LPC
(1 μM) was added (as an internal standard, IS) to 1.8 mL condi
tioned medium, which was mixed with 3 mL of methanol/chloroform (2 :1). The samples were mixed by vortexing for 1 minute and
incubated on ice for 10 minutes. Chloroform (1 mL) was added to
separate the phases, and the samples were mixed by vortexing for
1 minute and then centrifuged (1750g for 10 minutes, at 4 °C).
The lower phase was transferred to a new glass tube. The upper
phase was re-extracted and the lower phases were combined. The
experiment was performed at least seven times independently, each
in triplicate. Arachidonic acid was extracted using ethyl acetate
(27). In brief, 1 mL of conditioned medium from each sample was
mixed with 3 mL of ethyl acetate, and 10 pL of HC1 was added.
The samples were vortexed for 1 minute and then centrifuged
(1750g for 10 minutes, at 4 °C). The upper phase was transferred
to a new glass tube, the solvent was evaporated under nitrogen
at room temperature, and the dried lipids were resuspended in
100 pL of methanol for mass spectrometry (MS) analyses.
MS analyses of lipid extracts from conditioned media samples
were performed using API-4000 LC-MS-MS (Applied Biosystems∕
MDS SCIEX). Data processing was highly automated using the
mass spectrometer software and Excel. Samples (10 pL) were
directly delivered into the electrospray ionization source through
the LC system (Agilent 1100) with an autosampler. The mobile
phase was methanol/water/AmOH (90:10:0.1, vol/vol/vol) with a
flow rate of 0.1 mL∕min and 3 minutes for each sample. Quantitative
analyses were performed using the methods described previously
(28,29) in the multiple reaction monitoring mode. The peak inten
sity ratios (standard/IS) versus the concentration ratios (standard/
IS) were plotted and fitted using linear regression. At least seven
independent experiments were performed, each in triplicate.
Statistical Analysis

Data are presented as means with 95% confidence intervals (CIs)
of at least three independent experiments. Different values among
groups were compared using Student’s t test. All statistical tests
were two-sided, and P values less than .05 were considered to be
statistically significant.

Results
The Metastatis Suppressive Role of OGR1 In Vivo

Expression of OGR1 has been shown to be fivefold lower in meta
static tumors than in primary prostate tumors (24), implying that
OGR1 may have an inhibitory role in tumor metastasis. To inves
tigate the direct role of OGR1 in tumor metastasis, we established
several PC3 cell clones that stably overexpress OGR1. PC3 cells
were chosen because of their high metastatic potential and because
they have been used successfully in mouse models of metastatic

Fig. 1. Ovarian cancer G protein-coupled receptor 1 (OGR1) mRNA
expression in PC3 clones. PC3 human prostate cancer cells were trans
fected with one of the following DNA constructs: control retrovirus
vector-enhanced green fluorescence protein (pMSCV-EGFP), pMSCV
alone, pMSCV-OGR1-EGFP, or pMSCV-OGR1. Stable clones were
selected by puromycin treatment (2.5 μg/mL). OGR1 expression in sta
ble clones was analyzed by reverse transcription-polymerase chain
reaction. Controls were clones selected from PC3 cells transfected with
control vectors pMSCV and pMSCV-EGFP. Samples #1 and #2 were
single stable clones and sample #3 was pooled (mixing several different
single stable EGFP-positive) OGR1-EGFP-PC3 clones. Samples #4, #5,
and #6 were OGR1-PC3 clones (without EGFP). The housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the
loading control. One representative image of three independent experi
ments is shown.

prostate cancer (30). All the OGR1-PC3 clones used in this report
expressed 4-fold to 10-fold more OGR1 mRNA than parental PC3
cells, as assessed by quantitative PCR (data not shown).
Stable clones of PC3 cells that were transfected with vector
controls (vector-PC3 and EGFP-PC3) expressed very low levels of
endogenous OGR1 mRNA (Figs. 1 and 2, G). However, cells that
were transfected with OGR1 expression vectors (OGR1-PC3 or
OGR1-EGFP-PC3) overexpressed OGR1 (Fig. 1). To avoid dif
ferential effects resulting from different OGR1 insertion sites
across clones, both selected single-cell clones and a pooled clone
(a pool of several selected single-cell clones) of PC3 cells were used
in subsequent experiments. OGR1 was fused to EGFP to enable
easy observation and analysis of PC3-derived primary and meta
static tumors using fluorescence microscopy. However, to avoid
potential EGFP-related nonspecific effects, we also transfected
cells with OGR1 plasmids without the EGFP fusion (OGR1-PC3
clone).
To study the effect of OGR1 on tumoriginesis and metastasis
in vivo, we used mouse models of metastatic prostate cancer.
Athymic and NOD/SCID mice were randomly divided into two
groups (three to eight mice per group), and PC3 clones were
injected orthotopically into the prostate gland of each mouse.
Forty-five days later, mice were killed and tumor development was
examined. Mice that had been injected with vector-PC3 or EGFPPC3 formed primary tumors in the prostate glands and metastatic
tumors in the liver, spleen, kidney, stomach, lung, lymph nodes,
diaphragm, and mesentery (Fig. 2, A-C; arrows indicate tumor
loci). In contrast, the mice that were injected with the OGR1-PC3
or OGR1-EGFP-PC3 clones developed tumors that were con
fined to the prostate gland and did not metastasize to any of the
other organs examined (Fig. 2, A-C). To rule out a potential nonspecific effect of EGFP, we also tested the effect of OGR1-PC3
(without EGFP fusion) cells in mice, using the vector-PC3 cells as
the control.
We conducted four independent sets of experiments (Table 1)
in athymic and NOD/SCID mice. Overall, we observed a statis
tically significant reduction in metastases when exogenous

Fig. 2 (continues)

Fig. 2. Ovarian cancer G protein-coupled receptor 1 (OGR1) expression
and PC3 cell metastasis in vivo. PC3 cells (5.0 × 106) from clones
expressing enhanced green fluorescence protein (EGFP) as a control
(CONTROL) or clones expressing OGR1-EGFP (OGR1) were injected
into the prostate lobes of 5- to 8 week-old athymic or NOD/SCID mice.
A and B) On day 45 after injection, athymic mice (A) or SCID mice (B)
were analyzed for metastasis to different organs or anatomic regions.
Examination of tumor development in different organs was performed
by light stereo microscopy (A, a and b and B, i-p) or fluorescence stereo
microscopy (A, c-p and B, a-f). C) Images of metastatic tumors (a and
b) and primary prostate tumors (athymic mice, c and b; NOD/SCID
mice, e and f) are shown. Arrows indicate the tumors derived from PC3
cells implanted into the prostate. The area surrounded by the dotted
lines indicates the primary prostate tumor. The size of the primary
tumor was quantified, and mean (95% confidence intervals) volumes
are shown in (g). D) EGFP expression in stable clones of control EGFPPC3 and OGR1-EGFP-PC3 in vitro. Equal number of cells were seeded
in a six-well plate, and images of the cells were captured with an epifluorescence microscope using ×40 magnification (a and b). Mean (and
95% confidence intervals) fluorescence intensity is shown (c). E) In vivo

primary prostate tumor cell proliferation assays were carried out by
injecting BrdU (intraperitoneally, 40 mg/kg body weight), which is
incorporated by proliferating cells (a and b). BrdU-positive cells were
quantified, and the mean (and 95% confidence interval) number of
stained cells is shown (c). F) Terminal transferase dUTP nick end label
ing assay of the primary tumor sections was performed to detect apoptotic cells. The brown color stained cells indicate the cells undergoing
apoptosis (arrow head). Mean (and 95% confidence intervals) numbers
of apoptotic cells per field are shown (c). G) OGR1 protein expression in
prostate tumors from mice injected with control (either vector-PC3 or
EGFP-PC3) or OGR1-PC3 (either OGR1-PC3 or OGR1-EGFP-PC3) cells
were analyzed by immunohistochemistry with an anti-human OGR1
antibody. H) Detection of potential miscroscopic metastatic tumors.
Small portions of the livers without overt tumors from mice injected
with control and OGR1-PC3 cells were collected, and total RNA was
isolated. A liver metastatic tumor from a control mouse was used as a
positive control (Cont). Reverse transcription-polymerase chain reac
tion was conducted using specific primers for EGFP and β-actin.
Samples in lanes 1-7 are from tissues without overt tumors. Five inde
pendent experiments were performed.

OGR1 was expressed in PC3 cells as compared with control cells.
Metastatic foci were not found in any organ (other than the pros
tate) in 28 out of 32 mice in OGR1 groups (OGR1-EGFP-PC3
and OGR1-PC3 as single-cell clones or a pooled clone) (Table
1). The remaining four mice in this group developed several
small tumors (mean = 12.50%, 95% CI = 4.08% to 29.93%) that
were localized to the mesentery (<2mm in size) (Table 1). In
contrast, all 26 control mice (mean = 100%, 95% CI = 83.97%
to 100%) injected with vector- or EGFP-PC3 cells had numer
ous metastatic foci in multiple organs (Table 1). In addition,
the metastases in control mice were larger (>2 mm) and often
fused together to form tumor aggregates (Fig. 2, A and Table
1). We did not observe bone metastases in either the control or
the OGR1 mice (data not shown), which is consistent with pre
vious reports using the same PC3 injection model (31,32). In
addition, we tested the potential existence of microscopic
tumors using PCR-based detection of EGFP in the liver samples
collected from both control (EGFP-PC3) and OGR1 (OGR1EGFP-PC3) groups. Although EGFP was detected in overt
tumors, no EGFP was detected in liver samples that appeared to
be tumor free, suggesting the absence of microscopic tumors
(Fig. 2, H).
We obtained similar results in athymic mice and NOD/SCID
mice (Fig. 2, B and Table 1), which do not have normal T and B
cells, suggesting that both T and B cells do not play an important
role in OGRl’s metastatis suppression effect. In addition, we per
formed immunohistochemistry using the CD49b (NK1.1) anti
body and found no difference in the number of natural killer (NK)
cells in tumor sections derived from control cells and OGR1expressing cells (data not shown), suggesting that NK cells may
also do not play an important role in OGRl’s metastasis suppres
sion effect.
We next compared growth of primary tumors in mice that were
injected with either vector control or OGR1-PC3 cells. These
mice developed primary prostate tumors that were similar in size,
suggesting that OGR1 did not affect primary tumor growth
(Fig. 2, A, o and p; Fig. 2, B, e-h; Fig. 2, C, c-f; Table 1).
The fluorescence intensity of the primary tumors in the OGR1
mice appeared lower than that of the control mice (compare
Fig. 2, A, o and p and Fig. 2, B, e and f). This difference was mainly
due to lower EGFP expression in the OGR1-EGFP-PC3 cells
compared with that in EGFP-PC3 cells (Fig. 2, B and D).
To further evaluate the effect of OGR1 overexpression on pri
mary tumor cell proliferation, we conducted BrdU incorporation
and terminal transferase dUTP nick-end labeling assays in xeno
graft tumors from the athymic or the NOD/SCID mice. We
observed that primary prostate tumors derived from vector control
and OGR1-PC3 cells had similar BrdU incorporation (Fig. 2, E).
Minimal apoptosis was detected in tumor sections derived from
both control and OGR1-expressing cells (Fig. 2, F), confirming
that OGR1 did not affect growth and apoptosis of the primary
tumors.
Thus, by the definition of metastasis suppressor gene (3,7), our
data support the hypothesis that OGR1 is a novel metastasis sup
pressor gene in prostate cancer. We also confirmed that tumors
derived from OGR1-PC3 cells still expressed OGR1 as assessed by
immunohistochemical staining (Fig. 2, G).

Table 1. Summary of analysis for metastasis and primary tumor
size in prostate cancer orthotopic mouse model using athymic
and SCID mice*

Characteristic

Control (N = 26)

Mice with
metastases
Number
26 of 26
Percent
100 (83.97 to 100)
(95% Cl)
Percent
reduction
Metastases
per mouse
≤2 mm, mean 101.4 (91.8 to 111.0)
(95% Cl)
>2 mm, mean 114.5 (107.9 to 121.0)
(95% Cl)
Primary tumor
size, cm3
Mean (95% Cl) 5.25 (5.07 to 5.42)

OGR1 (N = 32)

Pt

4 of 32
<.001
12.50 (4.08 to 29.9)

87.5

.56 (0.40 to 0.72) <.001
0 (0.0 to 0.0)

<.001

5.20 (4.99 to 5.41)

* Metastases were found in the liver, mesentery, intestine, stomach, spleen,
lymph node, kidney, diaphragm, and lung. In the control group, 16 SCID and
seven athymic mice were injected with EGFP-PC3 cells; three athymic mice
were injected vector-PC3 cells. In the OGR1 group, 16 SCID and five athymic
mice were injected with single clones of OGR1-EGFP-PC3 cells, four athymic
mice were injected with pooled clones of OGR1-EGFP-PC3 cells, and seven
athymic mice were injected with OGR1-PC3 cells. SCID = severe combined
immunodeficiency; OGR1 = ovarian cancer G protein-coupled receptor 1;
Cl = confidence interval; EGFP = enhanced green fluorescence protein.
t P values (two-sided) were calculated using Student's t test.

The Effect of OGR1 on Cell Migration and the
Involvement of Gαi Protein in the Inhibitory Effect

To determine the molecular mechanisms by which OGR1 suppresses
tumor metastasis, we examined the effect of OGR1 on cell migration
in vitro. We tested PC3 cell migration to several extracellular matrix
(ECM) proteins (fibronectin, laminin, vitronectin, collagen I, and
collagen IV) using transwell assays. OGR1 expression, either with or
without fusion to EGFP, statistically significantly inhibited cell
migration to vitronectin reduction compared with the controls
(mean percentage of cells migrated, 30.2% versus 100%, difference =
69.8%,95% CI = 63.0% to 75.9%;P<.OOl; Fig. 3, Aand C (CONT;
data from both vector-PC3 and EGFP-PC3 were taken as 100%.
OGR1#1 = OGR1-PC3 and OGR1#2 = EGFP-OGR1-PC3). Other
ECM proteins either induced low levels of haptotaxis of the parental
cells, and OGR1 expression did not induce as much of an effect with
the other ECM proteins as it did with vitronectin (data not shown).
Thus, vitronectin was chosen as the ECM for the remainder of the
migration assays. In contrast to OGR1, expression of GPR4, the G
protein-coupled receptor sharing the highest homology with OGR1,
did not affect PC3 cell migration to vitronectin, suggesting a specific
function of OGR1 (Fig. 3, A and B). We also conducted transendothelial
migration assays to mimic the intravasation process in vivo
and found that OGR1 also inhibited this activity to a similar extent
(70% inhibition) (Fig. 3, C). In addition, we performed cell migra
tion assays with C4-2 and DU145 prostate cancer cell lines (which
do not express endogenous OGR1, as assessed by PCR; data not
shown) and found that OGR1 statistically significantly inhibited
migration in both cell types similar to that of PC3 cells (70% reduc
tion in migration, P<.001 for both C2-4 and DU145) (Fig. 4, A),

Fig. 3. The effect of ovarian cancer G proteincoupled receptor 1 (OGR1) in cell migration to
vitronectin and the involvement of G protein
alpha-inhibitory subunit 1. Migratory properties of
vector- and OGR1-PC3 cells to vitronectin were
assessed using transwell assays. Stably trans
fected vector control-PC3 or OGR1-PC3 cells were
serum starved for 16 hours. Cells (1 × 105) in 300 μL
of serum-free RPMI were added to the upper
chamber of a vitronectin-coated transwell, and
300 μL of serum-free RPMI was added in the lower
chamber. A) Cell migration of control (CONT, vector-PC3 or EGFP-PC3) and two stable clones of
OGR1-PC3 cells (OGR1#1;OGR1-PC3, and OGR1#2;
OGR1-EGFP-PC3) and GPR4-PC3 (GPR4) are
shown. To compare effects of OGR1 and GPR4,
cells were transiently transfected with OGR1 and
GPR4 expression vectors or empty pcDNA3 vector
as control and serum starved, and migration
assays were conducted 48 hours after transfec
tion. B and C) Cell migration [transwell (B) and
transendothelial (C)] in OGR1-PC3 cells compared
with parental or vector-PC3 cells (***P<.001).
Rvalues were calculated using two-sided Student's
t test). More than 10 independent experiments
were performed in triplicate.

suggesting that OGR1 s inhibitory effect on cell migration is not
limited to PC3 cells.
To explore the mechanism of this inhibition, we tested the effect
of PTX on the cell migration of vector- and OGR1-PC3 cells.
PTX pretreatment stimulated cell migration of OGR1-PC3 cells
but had no effect on vector-PC3 cells, suggesting that activating
Gαi proteins, which are sensitive to PTX, are involved in OGR1induced inhibition of cell migration. To confirm this result, cells
were transfected with a dominant-negative form of Gαil and cell
migration was monitored as before. The dominant-negative form
of Gαil reversed the effect of OGR1 (Fig. 4, B), similar to that seen
with PTX, confirming the involvement of a Gαil protein in
OGR1's inhibitory effect. Because migration is a critical step in
tumor metastasis, the reduced cell migration in vitro may be

related to the reduced tumor metastasis that was observed in vivo.
To explore how OGR1 regulates Gαil, we tested whether OGR1
expression alters Gαil protein expression. In two pairs of control
and OGR1-overexpressing cell lines (pair #1; vector-PC3 and
OGR1-PC3 and #2; EGFP-PC3 and OGR1-EGFP-PC3), OGR1
expression increased the expression of Gαil protein, which was
blocked by actinomycin D treatment, suggesting that the regula
tion was at the transcriptional level (Fig. 4, C).
To determine whether OGR1 affects cell proliferation in vitro,
we conducted cell proliferation assays (both cell number count and
MTT assays) in the presence (2% FBS) or absence of growth
stimulation (0% FBS). Cells from different clones (vector-PC3 and
OGR1-PC3) were incubated in serum-free media, and cell prolif
eration was determined after 24, 48, and 72 hours. Similar to what

Fig. 4. The effect of ovarian cancer G protein-coupled receptor 1 (OGR1)
on cell migration toward vitronectin in two other prostate cancer cell
lines, C2-4 and DU145. A) C2-4 (solid bars) and DU145 (open bars) cells
were transiently transfected with empty vector or a OGR1 plasmid and
subjected to migration assay as in Fig. 3. B) Effects of treatment with
pertussis toxin (PTX) (100 ng∕mL) for 16 hours or transfection (1.5 μg of
DNA per six-well plate) with a dominant-negative (DN-) form of
G protein alpha-inhibitory subunit 1 (Gαi1) on the inhibition of OGR1PC3 cells migration. In A and B, mean (and 95% confidence intervals)

percentages of migrated cells (result from four independent experi
ments in triplicate) are shown. P values (two-sided) were calculated
using Student's t test. C) lmmunoblotting was performed to test the
effect of OGR1 on the expression of Gαi1 protein level in two pairs of
the control and the OGR1 cell lines in the absence (pair #1; vector-PC3
and OGR1-PC3 and #2; EGFP-PC3 and OGR1-EGFP-PC3) or in the pres
ence of actinomycin D (pair#2 + ActD). The membrane was reprobed
for β-actin to check for equal loading. One representative blot from
three independent experiments is shown.

Fig. 5. Effects of ovarian cancer G protein-coupled
receptor 1 (OGR1) expression on prostate cancer
cell proliferation. In vitro cell proliferation assays
were carried out in 48-well plates. Vector- or
OGR1-PC3 cells (5 × 103) were cultured in RPMI
with or without 2% fetal bovine serum. Cell prolif
eration was assessed by counting the cells (A
and B) or by methylthiazolyldiphenyl-tetrazolium
assays (C and D) at each time point. Mean (and
95% confidence intervals) numbers of cells
counted by hemocytometer or absorbance inten
sity at 570 nm for one representative experiment
performed in triplicate of more than ten indepen
dent experiments with similar results are shown.

was observed in vivo, OGR1 expression did not affect cell prolifer
ation (Fig. 5). These results suggest that the in vitro behavior of the
cells may reflect, at least in part, their in vivo properties and, thus,
that some of their signaling mechanisms can be studied in vitro.

To test whether OGR1's inhibitory effect on cell migration is
mediated by the secretion of a soluble factor, conditioned media
was collected front vector-PC3 and OGR1-PC3 cells. Parental
PC3 cells were then treated with this conditioned media and
subjected to cell migration assays. Conditioned media from the

OGR1-PC3 cells, but not vector-PC3 cells, inhibited the migra
tion (mean percentage of cells migrated, 36.1% versus 100%, dif
ference = 63.9%, 95% CI = 60.8% to 67.1%; P<.001) of parental
PC3 cells (Fig. 6, A). The extent of this inhibition (60%-65%) is
similar to that measured in the OGR1-PC3 cell migration assays
(~70%). Collectively, these results suggest that a soluble factor(s)
secreted into the conditioned media derived from OGR1-PC3 cells
is responsible for the majority of the inhibitory effect on tumor cell
migration (Fig. 3). To determine whether the conditioned media
was required during cell migration or whether a short incubation
time was sufficient for successful suppression, the parental cells

Fig. 6. Effects on the secretion of an antimigratory lipid factor in a
G protein alpha-inhibitory subunit-dependent manner by ovarian
cancer G protein-coupled receptor 1 (OGR1). A) Parental PC3 cells
were incubated for 16 hours in serum-free RPMI medium, treated
with trypsin-EDTA, washed twice with phosphate-buffered saline
(PBS), and replated in conditioned media (CM) collected from either
vector-PC3 or OGR1-PC3 cells for 30 minutes at 37 °C. Controls were
treated as above but only washed twice with PBS after 30-minute
incubation (CM removed). To test the effect of heated conditioned
media on migration (CM heated), media from either vector-PC3 or
OGR1-PC3 cells was preheated at 95 °C for 30 minutes and then
incubated with parental PC3 cell before the cells were subjected to
the migration assay. Mean (and 95% confidence intervals) percent
age of cells migrated are shown for one representative of four inde

pendent experiments performed in triplicate (n = 3). B) The effect of
lipid extracts prepared from serum-starved (RPMI) and vector-PC3
(CONT) or OGR1-PC3 (OGR1) cells on cell migration. Mean (and con
fidence intervals) percentage of cells migrated are shown for one
representative of four independent experiments (performed in tripli
cate). C) Vector-PC3 (closed bars) and OGR1-PC3 (open bars) cells
were either untreated (CONT) or pretreated with 100 ng/mL of per
tussis toxin (PTX) for 12 hours. Cells were washed twice with PBS
and incubated in serum-free RPMI for 12 hours. The conditioned
media was then collected from PTX-pretreated cells and used to
access its effect on parental PC3 cells migration. Mean (and 95%
confidence intervals) percentage of cells migrated are shown for one
representative of four independent experiments performed in tripli
cate. P values (two-sided) were calculated using Student's t test.

Secretion of an Antimigratory Factor Induced by 0GR1

Fig. 7. The effect of sphingosylphosphorylcholine
(SPC) and proton-sensing function of ovarian
cancer G protein-coupled receptor 1 (OGR1) on
cell A) Control- or OGR1-PC3 cells were incu
bated in serum-free RPMI for 12 hours and then
untreated (-) or treated (+) with SPC (1 μM) for 30
minutes. Migration assays were then performed
as described in Materials and Methods. B) PC3
cells were transiently transfected with 1.0-1.5 μg
control vector (CONT), wild-type OGR1 (OGR1WT), or proton-sensing OGR1 mutant DNA
(OGR1-H245F). Cells were then incubated for 24
hours and then serum starved for an additional
12 hours before migration assays were per
formed. In A and B, mean (and 95% confidence
intervals) percentage of cells migrated are shown
for one representative of four independent exper
iments (performed in triplicate). C and D) Controlor OGR1-PC3 cells were incubated in physiologic
salt solutions of different pHs for 90 minutes.
Arachidonic acid (AA, C) and lysophosphatidylcholine (LPC, D) were extracted from the cell
supernatants and quantified. Mean (and 95%
confidence intervals) concentrations of AA ad
LPC are shown for one representative of five
independent experiments performed in triplicate.
None of the comparisons between control versus
OGR1 in Figs C and D were statistically signifi
cantly different (P values were all >.3, as deter
mined using a [two-sided] Student's t test).

were pre-incubated in conditioned media for 30 minutes. The
conditioned media was then removed by centrifugation, and the
cells were resuspended in serum-free media before cell migration
assays were performed. The inhibitory effect of the conditioned
media was lost when the conditioned media was removed before
the cell migration assay (Fig. 6, A), suggesting that a longer prein
cubation time or the presence of the inhibitory factor during the
cell migration is necessary.
As the first step to identify the nature of this soluble factor, the
conditioned media from OGR1-PC3 cells was heated to 95 oC for
30 minutes before migration assays were performed using paren
tal PC3 cells. After heating, the conditioned media retained its
antimigratory activity (Fig. 6, A), suggesting that a lipid factor is
involved. However, because not all protein/peptide factors are heat
labile, we cannot rule out the possible involvement of a heat-stable
peptide factor in this process. To further investigate the nature of
the factor, organic solvent extracts were prepared from condi
tioned media collected from OGR1-PC3, parental PC3, vectorPC3 cells, and serum-free media using chloroform/methanol
extraction (2 :1 vol/vol) and tested in migration assays as previously
described. Parental PC3 cells that were pretreated with solvent
extracts from OGRl-PC3-conditioned media migrated statisti
cally significantly less (mean percentage of cells migrated = 25.0%,
95% CI = 22.7% to 27.3%, P<.001) than cells treated with solvent
extracts from either the conditioned media from vector-PC3
(110%, 95% CI = 106.6% to 113.4%) or the serum-free media
(100%, 95% CI = 63.8% to 136.2%). These results strongly sug
gest that the factor secreted in conditioned media derived from
OGR1-PC3 cells is hydrophobic in nature.
To determine whether Gαi protein activation is involved in
OGRl-induced secretion of this inhibitory factor, OGR1-PC3
cells were pretreated with PTX before conditioned media was col
lected. The effect of PTX-treated conditioned media fromvector-

and OGR1-PC3 cells on cell migration of parental PC3 cells was
then compared. Although PTX did not affect migration induced
by the conditioned media from the vector control cells, it reversed
the inhibitory effect of the conditioned medium from OGR1-PC3
cells on cell migration (control versus OGR1: mean percentage of
cells migrated, 98.7% versus 36.1%, difference = 62.6%, 95% CI =
50.61% to 74.57%; P<.001; Fig. 6, C), suggesting that Gαi pro
tein activity is necessary for secretion of the inhibitory factor.
Because control cells (vector-PC3 or EGFP-PC3) did not
secrete a stimulatory factor in their conditioned media (Fig. 6, B), it
is likely that OGR1 expression enhances secretion of an inhibitory
factor(s) instead of inhibiting secretion of a stimulatory factor. Thus,
we expected to observe an increased amount of a hydrophobic factor
in conditioned media from OGR1-PC3 cells compared with condi
tioned media from control cells. AA and LPC are the two major
products of phospholipase A, (PLA2) enzymes, and some of LPC’s
biologic activities may be mediated by the OGR1 subfamily of G
protein-coupled receptors (14,33,34). However, we found that
OGR1 expression did not increase secretion of either AA or LPC
into the media at physiologic pH (7.4) (Fig. 7, C and D). Therefore,
AA and LPC are unlikely to be involved in the inhibitory effect on
migration. We also compared other positively or negatively charged
ions in the range of 100-1000 kDa from the solvent extracts from
the conditioned media from the control versus OGR1 samples using
MS (data not shown). No molecular species were consistently
increased in the lipids extracts from OGR1-PC3 cells.
Effects of SPC or OGR1's Proton-Sensing Activities on
the OGR1 Antimigratory Phenotype

We and others have observed that OGR1 has constitutive activity
(15,35,36). The in vivo and in vitro effects of OGR1 presented
above were measured in the absence of exogenous stimuli (other
than ECM proteins) and with a constant extracellular pH. Therefore,

the activities measured are likely to be mediated through the con
stitutive activation of OGR1.
To determine whether SPC influences the inhibitory effect of
OGR1 on cell migration, we treated vector- and OGR1-PC3 cells
with SPC (1 μM). SPC itself had an inhibitory effect on cell
migration (Fig. 7, A) that was not affected by OGR1 expression.
OGR1 has also been shown to have proton-sensing activity dur
ing inositol phosphate formation in the human embryonic kidney
HEK293 and other cell types (20,25). In our experiments, the pH
of the media was not changed, and therefore, it was unlikely that
the proton-sensing activity of OGR1 is involved in OGRl’s effect
on cell migration. To further address this issue, we constructed an
OGR1 mutant (OGR1-H245F) that has impaired proton-sensing
ability (25). OGR1 H245F showed a similar inhibitory effect on
cell migration as wild-type OGR1 (Fig. 7, B). Furthermore, we
tested the effect of pH on AA and LPC secretion related to
OGR1 expression and found that OGR1 expression did not affect
AA and LPC production or secretion at any of the pHs tested
(Fig. 7, C).

Discussion
Metastasis suppressor genes are a class of genes that reduce the
metastatic propensity of cancer cell lines in vivo without affecting
their tumorigenesis (2-4). In this article, we presented the follow
ing evidence to support the hypothesis that OGR1 is a novel
metastasis suppressor gene in prostate cancer: 1) when OGR1 was
overexpressed in PC 3 cells, it suppressed tumor cell metastasis in an
orthotopic mouse model of prostate cancer; 2) OGR1 did not affect
primary tumor growth, as assessed by the size of the primary
tumors and by BrdU incorporation assays; and 3) in vitro, OGR1
expression reduced cell migration, an important step in metastasis,
without affecting cell proliferation. These data, together with a
previous report showing that OGR1 expression is reduced in meta
static compared with primary prostatic tumors (24), support the
hypothesis that OGR1 may have an important role in the metastasis
of prostate cancer cells.
OGR1 has been shown to suppress tumor cell growth in ovar
ian cancer cells (36,37). When OGR1 was expressed fourfold
to 10-fold above basal levels in PC3 cells, it did not affect cell
growth. GPR4, a G protein-coupled receptor sharing more than
50% homology with OGR1, did not inhibit cell migration, sug
gesting a specific antimigratory role for OGR1. These results
are consistent with an earlier report showing that GPR4 is
oncogenic (38).
OGR1 has been shown to have a proton-sensing activity (17,25)
that may be cell-type and signaling pathway specific (15,25).
Because an acidic extracellular pH—a characteristic of the microenvironment of solid tumors—has been shown to enhance tumor
metastatic potential (39), we have addressed the potential role of
the proton-sensing ability of OGR1 in our assays. An OGR1
mutant (H245F) with minimal proton-sensing activity in inositol
phosphate accumulation had the same effect as wild-type OGR1
on PC3 cell migration. Furthermore, OGR1 does not affect AA or
LPC secretion at different pHs as compared with the control. In
addition, OGRl’s proton sensing activity is mediated by a Gαq
protein (40). We have observed that a dominant-negative Gαq had

no effect on OGRl’s effect on cell migration (data not shown) and
Gαil mediates the OGRl’s effect.
OGR1 and related G protein-coupled receptors may have
dual functions for mediating signals from either lipids or protons
(19,20,41). SPC, a bioactive lipid molecule, is able to modulate the
proton-sensing activity of OGR1. In Chinese hamster ovary cells,
SPC inhibits the acid-induced actions in a pH-dependent manner
(42). We tested the effect of SPC on migration of PC3 cells and
found that it was inhibitory. However, this inhibitory effect
appeared to be independent of OGR1 expression. We cannot com
pletely rule out that SPC may have an effect in vivo. These issues
warrant further studies. Together, our data suggest that the
in vitro effects of OGR1 described in this article are unlikely to
be related to SPC or proton sensing and are constitutive in nature.
The mechanisms of OGRl’s inhibitory effect on cell migration
appeared to be related to Gαil protein activation. G proteincoupled receptor constitutive activity can induce G protein
activation. Interestingly, prostate cancer cells express relatively low
levels of Gαi proteins, which may have an important regulatory
role in cell proliferation and neoplastic transformation in these
cells (43). In addition, immunoblot analysis shows that although
the levels of β subunits of G proteins are maintained, those of αs
and αi subunits are decreased 30%-40% after neoplastic transfor
mation (43). We showed here that OGR1 expression increased
Gαil expression in PC3 cells and that this increase was likely to be
at the transcriptional level.
Gi protein activation is involved in the stimulation of cell
migration and in intracellular signaling through receptors for
lysophosphatidic acid and sphingosine-1-phosphate (44—47). In
contrast, Gi protein-mediated inhibition of cell migration is much
less explored. Nevertheless, it has been shown that a Gi-mediated
inhibition of cAMP accumulation is involved in the inhibitory
effect of angiopeptin on the migration of vascular smooth muscle
cells (48).
The present study has several limitations. Only one prostate
cancer cell line was used in the in vivo models. OGRl’s function
in additional prostate cell lines should be tested in vivo. Bone
metastasis is a major issue for human prostate cancer. The role of
OGR1 in bone metastasis has not been assessed because we did
not observe bone metastases in either the control or the OGR1
mice. This issue should be tested in different prostate cancer
models. In addition, we have not identified the soluble factor that
is responsible for the inhibitory effect of OGR1 on cell migration.
It is possible that the migration inhibitory factor is present at
lower concentrations and thus difficult to detect. It is also possible
that the size or charge of the molecule is outside the detection
range that we chose. Further studies are required to identify this
factor. Nevertheless, our results do suggest that Gi protein activa
tion is involved in the secretion of this OGR1-induced inhibitory
factor.
Our results show that OGR1 suppresses prostate cancer metas
tasis without affecting primary tumor progression, suggesting that
OGR1 is a novel metastasis suppressor gene for prostate cancer.
Activation of Gil and the secretion of a hydrophobic factor appear
to be important for OGRl’s antimetastatic action. Further investi
gation needs to be conducted to identify the soluble factor(s)
involved in this process.
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